Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Genfit - 2023

72 Posts
Pagina: «« 1 2 3 4 | Laatste | Omlaag ↓
  1. forum rang 4 Kanhetlager 11 november 2024 15:53

    • Kanhetlager

      Lid sinds: 11 jul 2024

      Laatste bezoek: 05 mrt 2025

    • Aanbevelingen

      Ontvangen: 270

      Gegeven: 298

    •    Aantal posts: 734

    quote:

    Pjotr schreef op 8 november 2024 18:07:

    Geen beste dag voor Genfit. Bijna 10% eraf
    Geen herstel vandaag. Toch net wat gekocht.
  6. Pjotr 4 december 2024 09:22

    • Pjotr

      Lid sinds: 04 jan 2018

      Laatste bezoek: 21 mrt 2025

    • Aanbevelingen

      Ontvangen: 172

      Gegeven: 110

    •    Aantal posts: 517

    een maand geleden werd er flink gekocht boven de 5 euro. Zoveel is er toch niet veranderd.
  8. forum rang 4 Kanhetlager 6 december 2024 11:35

    • Kanhetlager

      Lid sinds: 11 jul 2024

      Laatste bezoek: 05 mrt 2025

    • Aanbevelingen

      Ontvangen: 270

      Gegeven: 298

    •    Aantal posts: 734

    quote:

    Pjotr schreef op 4 december 2024 09:22:

    een maand geleden werd er flink gekocht boven de 5 euro. Zoveel is er toch niet veranderd.
    Was dat niet vanwege overnamespeculatie?
  12. forum rang 10 DeZwarteRidder 30 januari 2025 13:56

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 22 mrt 2025

    • Aanbevelingen

      Ontvangen: 24687

      Gegeven: 10676

    •    Aantal posts: 102.627

    GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

    January 30, 2025 02:40 ET | Source: GENFIT S.A.

    Share

    GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital:
    €130 million upfront, with eligibility to receive up to €55 million in two additional instalments based on near-term milestones
    Closing subject to approval by the 2025 OCEANE bondholders at upcoming bondholders meeting
    Financing would extend cash runway beyond the end of 2027, assuming drawdown of all instalments
    Proceeds to further strengthen the development of the ACLF pipeline
    In return, HCRx will receive a portion of royalties on global1 sales of Iqirvo® (elafibranor) payable to GENFIT under its licensing agreement with Ipsen, up to an agreed upon cap after which all future royalties will revert back to GENFIT
    GENFIT retains rights to all future regulatory, commercial and sales-based milestone payments from Ipsen under the Ipsen agreement
    GENFIT to concurrently propose a repurchase of the 2025 OCEANEs aiming to completely eliminate GENFIT’s convertible debt overhang

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 30, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), today announces that it has entered into a non-dilutive capped royalty financing agreement with HealthCare Royalty (HCRx) for up to €185 million, and debt overhang resolution plan.

    Pascal Prigent, CEO of GENFIT, commented: “This non-dilutive financial agreement is a pivotal step in strengthening our financial outlook, extending our cash runway beyond 2027. We are also proposing to repurchase the outstanding 2025 OCEANE bonds to eliminate our convertible debt overhang. This financing transaction will position GENFIT to operate on strong foundations to deliver on its R&D pipeline objectives in ACLF.”

    Clarke Futch, Chairman and Chief Executive Officer of HCRx, added: “With this investment, HCRx underscores its commitment to supporting innovative biopharmaceutical companies that create long-term value. We firmly believe in the strong potential that Iqirvo® delivers to patients with high unmet medical need, and are excited to collaborate with GENFIT on this transaction.”

    Highlights

    Corporate context

    In December 2021, GENFIT entered into a long-term strategic partnership with Ipsen (the “Ipsen agreement”). The agreement grants Ipsen an exclusive worldwide license (excluding China, Hong Kong, Taiwan and Macau for which Terns Pharmaceuticals has a prior license) to develop, manufacture, and commercialize elafibranor for people living with Primary Biliary Cholangitis (PBC), and in other indications. Under the terms of the Ipsen agreement, GENFIT is eligible for regulatory, commercial, and sales-based milestone payments and royalties, based on product sales.

    In 2024, Iqirvo® (elafibranor) received accelerated approval from the U.S. Federal Drug Administration for sale in the United States and conditional
72 Posts
Pagina: «« 1 2 3 4 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.106
AB InBev 2 5.531
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.078
ABO-Group 1 23
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.829
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.804
Aedifica 3 925
Aegon 3.258 323.042
AFC Ajax 538 7.088
Affimed NV 2 6.305
ageas 5.844 109.901
Agfa-Gevaert 14 2.062
Ahold 3.538 74.349
Air France - KLM 1.025 35.265
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.049
Alfen 16 25.180
Allfunds Group 4 1.516
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 418
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.748
AMG 971 134.231
AMS 3 73
Amsterdam Commodities 305 6.744
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 495
Antonov 22.632 153.605
Aperam 92 15.047
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.798
Arcelor Mittal 2.034 320.943
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.350
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.597
ASML 1.766 109.805
ASR Nederland 21 4.507
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.834
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.447

Macro & Bedrijfsagenda

  1. 24 maart

    1. Samengestelde inkoopmanagersindex maart (Jap)
    2. Samengestelde inkoopmanagersindex maart (Fra)
    3. Samengestelde inkoopmanagersindex maart (Dld)
    4. Samengestelde inkoopmanagersindex maart (eur)
    5. Samengestelde inkoopmanagersindex maart (VK)
    6. Chicago Fed index februari (VS)
    7. Samengestelde inkoopmanagersindex maart (VS)

  2. 25 maart

    1. Ifo ondernemersvertrouwen maart (Dld)
    2. Case Shiller huizenprijzen januari (VS)
    3. Shell beleggersdag
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda